Press Release: Advanced Accelerator Applications : Theragnostics Announces Licensing Agreement for Development and Commercialization of One-Step PET Radiopharmaceuticals

LONDON, Sept. 22, 2021 /PRNewswire/ -- Theragnostics, which is developing molecular radiotherapy for imaging and treating a broad range of cancers, announces that it has signed a global licensing agreement with Advanced Accelerator Applications S.A. ("AAA"), a Novartis company, to develop...